Long-term pharmacological activation of PPARγ does not prevent left ventricular remodeling in dogs with advanced heart failure

Cardiovascular Drugs and Therapy

Volumn 21, Issue 1, 2007, Pages 29-36

  Suzuki, George ^a   Khanal, Sanjaya ^a   Rastogi, Sharad ^a   Morita, Hideaki ^a   Mishima, Takayuki ^a   Anagnostopoulos, Petros V ^a   Nass, Omar ^a   Sharov, Victor G ^a   Tanhehco, Elaine J ^a   Goldstein, Sidney ^a   Sabbah, Hani N ^a,b  

^a HENRY FORD HEART AND VASCULAR INSTITUTE   (United States)

^b HENRY FORD HOSPITAL   (United States)

Author keywords

Drugs; Heart failure; Hemodynamics; Remodeling

Indexed keywords

CYTOKINE; GW 347845; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 6; MESSENGER RNA; MITOGEN ACTIVATED PROTEIN KINASE P38; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA AGONIST; PROTEIN P21; TRANSCRIPTION FACTOR; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANGIOGRAPHY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA PRESSURE; ARTICLE; ARTIFICIAL EMBOLISM; BODY WEIGHT; COMPARATIVE STUDY; CONTROL GROUP; CONTROLLED STUDY; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MEGADOSE; EXPERIMENTAL DOG; FOLLOW UP; GENE EXPRESSION; HEART FAILURE; HEART HEMODYNAMICS; HEART LEFT VENTRICLE; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE ENDDIASTOLIC PRESSURE; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART MUSCLE CELL; HEART RATE; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE REMODELING; HEART WEIGHT; INFLAMMATION; LOW DRUG DOSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; SYSTOLE; TISSUE SECTION; TREATMENT DURATION; UPREGULATION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ADMINISTRATION, ORAL; ANIMALS; ATRIAL NATRIURETIC FACTOR; BODY WEIGHT; CYTOKINES; DISEASE MODELS, ANIMAL; DOGS; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; HEART FAILURE; HEART RATE; MYOCARDIUM; ORGAN SIZE; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PPAR GAMMA; PROTEIN KINASES; PROTO-ONCOGENE PROTEINS P21(RAS); PTEN PHOSPHOHYDROLASE; RNA, MESSENGER; STROKE VOLUME; VENTRICULAR FUNCTION, LEFT; VENTRICULAR REMODELING;

EID: 34247137270     PISSN: 09203206     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10557-007-6003-9     Document Type: Article

References (45)

1. Breider MA, Gough AW, Haskins JR, Sobocinski G, de la Iglesia FA. Troglitazone-induced heart and adipose tissue cell proliferation in mice. Toxicol Pathol 1999;27:545-52.
2. Tai TA, Jennermann C, Brown KK, Oliver BB, MacGinnitie MA, Wilkison WO, et al. Activation of the nuclear receptor peroxisome proliferators-activated receptor gamma promotes brown adipocyte differentiation. J Biol Chem 1996;271:20090-114.
3. Lee MK, Miles PD, Khoursheed M, Gao KM, Moossa AR, Olefsky JM. Metabolic effects of troglitazone on fructose-induced insulin resistance in the rat. Diabetes 1994;43:1435-40.
4. Kelly DP. PPARs of the heart. Circ Res 2003;92:482-4.
5. Shimabukuro M, Higa S, Shinzato T, Nagamine F, Komiya I, Takasu N. Cardioprotective effects of troglitazone in streptozotocin-induced diabetic rats. Metabolism 1996;45:1168-73.
6. Jiang C, Ting AT, Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998; 391:82-6.
7. Takano H, Nagai T, Asakawa M, Toyozaki T, Oka T, Komuro I, et al. Peroxisome proliferators-activated receptor activators inhibit lipoplysaccharide-induced tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes. Circ Res 2000;87:596-602.
8. Lee TM, Chou TF. Troglitazone administration limits infarct size by reduced phosphorylation of canine myocardial connexin43 proteins. Am J Physiol Heart Circ Physiol 2003;285:H1650-9.
9. Zhu P, Lu L, Xu Y, Schwartz GG. Troglitazone improves recovery of left ventricular function after regional ischemia in pigs. Circulation 2000;101:1165-71.
10. Nemoto S, Razeghi P, Ishiyama M, De Freitas G, Taegtmeyer H, Carbello BA, et al. PPARγ agonist rosiglitazone ameliorates ventricular dysfunction in experimental chronic mitral regurgitation. Am J Physiol Heart Circ Physiol 2004;288:H77-82.
11. Xu Y, Gen M, Lu L, et al. PPARγ activation fails to provide myocardial protection in ischemia and reperfusion in pigs. Am J Physiol Heart Circ Physiol 2005;288:H1314-23.
12. Wang CH, Weisel RD, Liu PP, Fedak PWM, Verma S. Glitazones and heart failure: critical appraisal for the clinician. Circulation 2003;107:1350-4.
13. Nesto RW, Ball D, Bonow RO, Fonseca V, Grundy SM, Horton ES, et al. Thiazolidine use, fluid retention, and congestive heart failure. A consensus statement from the Ameicarn Heart Association and the American Diabetes Association. Diabetes Care 2004;27:256-63.
14. Sabbah HN, Stein PD, Kono T, Gheorghiade M, Levine TB, Jafri S, et al. A canine model of chronic heart failure produced by multiple sequential coronary microembolizations. Am J Physiol 1991;260:H1379-84.
15. Sabbah HN, Shimoyama H, Kono T, Gupta RC, Sharov VG, Scicli G, Levine TB, et al. Effects of long-term monotherapy with enalapril, metoprolol, and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction. Circulation 1994;89:2852-9.
16. Li AC, Brown KK, Silvestre MJ, Wilson TM, Palinski W, Glass C. Peroxisome proliferator-activated receptor r ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 2000;106:523-31.
17. Grossman W: Pressure measurement. In: Grossman W, Baim DS editors. Cardiac catheterization, angiography, and intervention. Philadelphia: Lea & Febiger; 1991. p. 123.
18. Liu Yh, Yang XP, Sharov VG, Nass O, Sabbah HN, Peterson E, et al. Effects of angiotension-converting enzyme inhibitors and angiotension II type 1 receptor antagonists in rats with heart failure. Role of kinins and angiotension II type 2 receptors. J Clin Invest 1997;99:1926-35.
19. Deswal A, Petersen NJ, Feldman AM, Young JB, White BG, Mann DL. Cytokines and cytokine receptors in advanced heart failure: an analysis of the cytokine database from the Vesnarinone Trial (VEST). Circulation 2001;103:2055-9.
20. Torre-Aminone G, Kapadia S, Benedict C, Oral H, Young JB, Mann DL. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the Studies of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 1996;27 5:1201-6, Apr.
21. Deswal A, Bozkurt B, Seta Y, Parilti-Eiswirth S, Hayes FA, Blosch C, et al. Safety and efficacy of a soluble p75 tumor necrosis factor receptor (etanercept) in patients with advanced heart failure. Circulation 1999;99:3224-6.
22. Bozkurt B, Torre-Amione G, Warren MS, Whitmore J, Soran OZ, Feldman AM, et al. Results of targeted anti-tumor necrosis factory therapy with entanercept (ENBREL) in patients with advanced heart failure. Circulation 2001;103:1044-7.
23. Sliwa K, Skudicky D, Candy G, Wisenbaugh T, Sareli P. Randomized investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy. Lancet 1998;351:1091-3.
24. Mann DL, McMurray JJ, Packer M, Swedberg K, Borer JS, Colucci WS, et al. Targeted anticytokine therapy in patients with chronic heart failure: results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 2004;109:1594-602.
25. Ricote M, Li AC, Wilson TM, Kelly CJ, Glass CK. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998;391:79-82.
26. Shimoyama M, Ogino K, Tanaka Y, Ikeda T, Hisatome I. Hemodynamic basis for the acute cardiac effects of troglitazone in isolated perfused rat hearts. Diabetes 1999;48:609-15.
27. Ghazzi MN, Perez JE, Antonucci TK, Driscoll JH, Huang SM, Faja BW, et al. Cardiac and glycemic benefits of troglitazone treatment in NIDDM: the troglitazone study group. Diabetes 1997;46:433-9.
28. Delerive P, Martin-Nizard F, Chinetti G, Trottein F, Fruchart JC, Najib J, et al. Peroxisome proliferators-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 1999;85:394-402.
29. Buchanan TA, Meehan WP, Jeng YY, Yang D, Chan TM, Nadler JL, et al. Blood pressure lowering by pioglitazome. Evidence for a direct vascular effect. J Clin Invest 1995;96:354-60.
30. Asakawa M, Takano H, Nagai T, Uozumi H, Hasegawa H, Kubuto N, et al. Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation 2002;105:1240-6.
31. Williams GD, Deldar A, Jordan WH, Gries C, Long GG, Dimarchi RD. Thiazolidinedione, Tanabe-174 (LY282449), in the rat and dog. Diabetes 1993;42 Suppl:59A.
32. Bell D, McDermott BJ. Troglitazone does not initiate hypertrophy but can sensitize cardiomyocytes to grow effects the serum. Eur J Pharmacol 2000;390:237-44.
33. Breider MA, Gough AW, Haskins JR, Sobocinski G, de la Iglesia FA. Troglitazone-induced heart and adipose tissue cell proliferation in mice. Toxicol Pathol 1999;27:545-52.
34. Xin X, Yang S, Kowalski J, Gerritsen ME. Peroxisome proliferators- activated receptor gamma ligands are potent inhibitors of angiogenesis in vitro and in vivo. J Biol Chem 1999;274:9116-21.
35. Bishop-Bailey D, Hla T. Endothelial cell apoptosis induced by the peroxisome proliferators-activated receptor (PPAR) ligand 15-deoxy-Delta 12, 14-prostaglandin J2. J Biol Chem 1999;274:17042-8.
36. Wang CH, Weisel RD, Liu PP, Fedak PWM, Verma S. Glitazones and heart failure: critical appraisal for the clinician. Circulation 2003;107:1350-4.
37. Wooltron E. Rosiglitazone (Avandia) and pioglitazone (Actos) and heart failure. Can Medical Assoc J 2002;166:219.
38. Belcher GL, Michel JL. Tolerability profile of pioglitazone in combination with a sulfonyluria or metformin in controlled clinical trials. Diabetes 2001;49 Suppl 2:A416.
39. Aronoff SL. Adverse events with pioglitazone. Diabetes 2000;49 Suppl 1:A340.
40. St. John Sutton M, Rendell M, Dandona P, Dole JF, Murphy K, Patwardhan R, et al. A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 2002;25:2058-64.
41. Murphy GJ, Holder JC. PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer. Trends Pharmacol Sci 2000;21:469-74.
42. Sato H, Ishihara S, Kawashima K, Moriyama N, Suetsugu H, Kazumori H, Okuyama T, et al. Expression of peroxisome proliferators-activated receptor (PPAR) gamma in gastric cancer and inhibitory effects of PPARgamma agonists. Br J Cancer 2000;83:1394-400.
43. Su CG, Wen X, Bailey ST, Jiang W, Rangwala SM, Keilbaugh SA, et al. A novel therapy for colitis utilizing PPAR-gamma ligands to inhibit the epithelial inflammatory response. J Clin Invest 1999;104:383-9.
44. Kawahito Y, Kondo M, Tsubouchi Y, Hashiramoto A, Bishop-Bailey D, Inoue K, et al. 15-deoxy-delta (12,14)-PGJ(2) induces synoviocyte apoptosis and suppresses adjuvant-induced arthritis in rats. J Clin Invest 2000;106:189-97.
45. Dormandy JA, Charbonnel B, Eckland DJ, Erdmann E, Massi-Benedetti M, Moules IK, et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomized controlled trial. Lancet 2005;366:1279-89.